F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, cardiometabolic syndrome, cardiovascular disorders, Parkinson’s disease and Alzheimer’s disease.
Enanta Pharmaceuticals Inc. has announced a new immunology program and updated progress in its immunology pipeline. The company’s new program is focused on developing oral MRGPRX2 inhibitors for type 2 immune driven diseases, with an initial focus on chronic spontaneous urticaria and other mast cell-driven diseases.
Human respiratory syncytial virus (hRSV) represents a major global health burden and is a leading cause of severe respiratory disease, particularly among preterm infants. Despite extensive efforts to prevent hRSV infection, currently approved monoclonal antibody (mAb) therapies have been exclusively designed to target its surface fusion or pre-fusion protein (F-hRSV).
Cystic fibrosis (CF) is an autosomal recessive genetic disorder caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. Researchers from Sorbonne University and Hôpital Trousseau developed a targeted approach based on antisense oligonucleotides as a way to improve CF management.
Jiangsu Carephar Pharmaceutical Co. Ltd. has divulged angiotensin AT2 receptor (AGTR2) agonists reported to be useful for the treatment of idiopathic pulmonary fibrosis.
Bronchopulmonary dysplasia (BPD) remains a significant challenge in neonatal care, particularly affecting preterm infants with low birth weight who often require oxygen therapy or mechanical ventilation to survive.
Aché Laboratórios Farmacêuticos SA has synthesized compounds acting as β2-adrenoceptor (ADRB2) agonists and muscarinic M3 receptor antagonists reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and rhinitis.
Acute lung injury (ALI) is a severe condition marked by uncontrolled lung inflammation and tissue damage, often leading to respiratory failure. Excessive immune activation recruits neutrophils that release pro-inflammatory cytokines, including IL‑6 and TNF‑α, while generating reactive oxygen species (ROS) that damage DNA and trigger cell death. Thus, controlling inflammation and limiting ROS are key strategies to prevent ALI.
Recludix Pharma Inc. has obtained IND clearance from the FDA to advance REX-8756 (SAR-448755), an oral STAT6 inhibitor for inflammatory diseases, into phase I testing. REX-8756 is an oral, selective STAT6 inhibitor that employs a novel therapeutic approach by targeting STAT6’s SH2 domain.
RSS
